Subscribe To
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized ...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized ...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized ...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized ...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized ...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized ...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized ...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized ...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized ...
October 14, 2023, 8:30 pm
Ultragenyx and mereo biopharma announce interim phase 2 data from phase 2/3 orbit study demonstrating setrusumab (ux143) significantly reduced fracture rates in patients with osteogenesis imperfecta (
Phase 2 data presented at ASBMR 2023 show treatment with setrusumab resulted in 67% reduction in annualized ...
October 14, 2023, 8:30 pm
Usa compression partners announces third-quarter 2023 distribution; third-quarter 2023 earnings release and conference call scheduled for october 31
AUSTIN, Texas--(BUSINESS WIRE)--USA Compression Partners, LP (NYSE: USAC) (“USA Compression”) today announced a cash distribution of $0.525 per co...
October 12, 2023, 4:37 pm
Cable gives back two days of gains, nears 1.2200
The pound came into the day riding a six-day winning streak against the US dollar.USD was sliding on the hope that long-dated rates had peaked and tha...
October 12, 2023, 3:34 pm
Glo: continue to avoid this underperforming fund
The Clough Global Opportunities Fund relies on its star manager, Charles Clough, to make differentiated macro calls. Unfortunately, the fund has massi...
October 11, 2023, 11:07 pm
14% yield, 20% below book value - fs kkr is a bdc gem
FS KKR Capital Corp trades at a 20% discount to its book value, offering a high annualized yield of 14....
October 11, 2023, 10:44 am
Bitcoin is undervalued now — but just look at its projected long-term return
Bitcoin over the next 100 years will produce an annualized return of 1.1%. That’s the prediction of a...
October 10, 2023, 12:00 pm
T-mobile us: expect the market dominance to continue
Over the past ten years, TMUS has had an extraordinary run, surpassing both its competitors and the market by delivering returns that were at least do...
October 8, 2023, 9:00 am
7 stocks poised to benefit from strong economic growth in q4
All signs suggest that the U.S. economy is actually doing quite well. In the second quarter, U.S. GDP expanded at an impressive...
October 3, 2023, 9:00 pm
Sigma lithium on track to meet guidance as it achieves record peak production of 890 tonnes per day
Sigma Lithium Corp (TSX-V:SGML, NASDAQ:SGML) has announced that its Greentech Plant in Brazil has reached a record daily production of 890 tonnes, put...
October 3, 2023, 8:16 am
Sigma lithium says its greentech plant in brazil reached record daily peak production
(Kitco News) - Lithium producer Sigma Lithium (NASDAQ: SGML) (TSXV: SGML) announced today that its Greentech plant in Brazil has reached record daily ...
October 2, 2023, 4:03 pm
My top 10 high yield dividend stocks for october 2023
The market slide continues in September with the SPDR S&P 500 Trust ETF dropping by 4.74%. The top 10 stocks on the watchlist for October 2023 offer a...
October 1, 2023, 11:55 am